Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

Biochemical Journal

Volumn 385, Issue 2, 2005, Pages 399-408

  Barnett, Stanley F ^a   Defeo Jones, Deborah ^a   Fu, Sheng ^a   Hancock, Paula J ^a   Haskell, Kathleen M ^a   Jones, Raymond E ^a   Kahana, Jason A ^a   Kral, Astrid M ^a   Leander, Karen ^a   Lee, Ling L ^a   Malinowski, John ^a   McAvoy, Elizabeth M ^a   Nahas, Debbie D ^a   Robinson, Ronald G ^a   Huber, Hans E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; Allosteric inhibitor; Inhibitor; Kinase; Pleckstrin homology domain; Protein kinase B (PKB)

Indexed keywords

ADENOSINETRIPHOSPHATE; ANTIBODIES; BIOASSAY; CELL CULTURE; ENZYME KINETICS; PH EFFECTS;

HOMOGENEOUS TIME-RESOLVED FLUORESCENCE (HTRF) ASSAY; ISOENZYME SPECIFICITY; PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1); PHOSPHORYLATION;

ENZYME INHIBITION;

ADENOSINE TRIPHOSPHATE; ISOENZYME; PHOSPHATIDYLINOSITIDE DEPENDENT KINASE 1; PHOSPHATIDYLINOSITOL KINASE; PLECKSTRIN; PROTEIN KINASE B 1; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; STAUROSPORINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FLUORESCENCE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IC 50; MODEL; NUCLEOTIDE SEQUENCE; PLECKSTRIN HOMOLOGY DOMAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN;

ADENOSINE TRIPHOSPHATE; APOPTOSIS REGULATORY PROTEINS; BENZYLAMINES; BINDING, COMPETITIVE; BLOOD PROTEINS; CARCINOMA; CASPASES; CELL LINE, TUMOR; CLONING, MOLECULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; ISOENZYMES; MALE; MEMBRANE GLYCOPROTEINS; MOLECULAR STRUCTURE; PEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 19944433628     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20041140     Document Type: Article

References (53)

1. Mitsiades, C. S., Mitsiades, N., Koutsilieris, M., Nicholson, K. M., Anderson, N. G., Neri, L. M., Borgatti, P., Capitani, S., Martelli, A. M., Brazil, D. P. and Hemmings, B. A. (2004) The Akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 4, 235-256
2. Vivanco, I. and Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat. Rev. 2, 489-501
3. Brazil, D. P. and Hemmings, B. A. (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 26, 657-664
4. Simpson, L. and Parsons, R. (2001) PTEN: Life as a tumor suppressor. Exp. Cell Res. 264, 29-41
5. Vanhaesebroeck, B. and Alessi, D. R. (2000) The P13K-PDK1 connection: more than just a road to PKB. Biochem J. 346, 561-576
6. Besson, A., Robbins, S. M. and Yong, V. W. (1999) PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur. J. Biochem. 263, 605-611
7. Chan, T. O., Rittenhouse, S. E. and Tsichlis, P. N. (1999) AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem. 68, 965-1014
8. Alessi, D. R. and Cohen, P. (1998) Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8, 55-62
9. Masure, S., Haefner, B., Wesselink, J. J., Hoefnagel, E., Mortier, E., Verhasselt, P, Tuytelaars, A., Gordon, R. and Richardson, A. (1999) Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur. J. Biochem. 265, 353-360
10. Yang, J., Cron, P., Good, V. M., Thompson, V., Hemmings, B. A. and Barford, D. (2002) Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP Nat. Struct. Biol. 9, 940-944
11. Yang, J., Cron, P., Thompson, V., Good, V. M., Hess, D., Hemmings, B. A. and Barford, D. (2002) Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 9, 1227-1240
12. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B. and Cohen, P. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol. 7, 261-269
13. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F. and Hawkins, P. T. (1997) Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277, 567-570
14. Sulis, M. L. and Parsons, R. (2003) PTEN: from pathology to biology. Trends Cell Biol. 13, 478-483
15. Bonneau, D. and Longy, M. (2000) Mutations of the human PTEN gene. Human Mutat. 16, 109-122
16. Yeh, J. J. and Sellers, W. R. (2000) PTEN - Regulator of phosphoinositide 3-kinase signal transduction. In Tumor Suppressor Genes in Human Cancer (Fisher, D. E., ed.), pp. 231-251, Humana Press Inc, Totowa
17. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z. M., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M. et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16, 64-67
18. Marsh, D. J., Coulon, V., Lunetta, K. L., Rocca-Serra, P., Dahia, P. L. M., Zheng, Z. M., Liaw, D., Caron, S., Duboue, B., Lin, A. Y. et al. (1998) Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Human Mol. Genet. 7, 507-515
19. Arch, E. M., Goodman, B. K., Van Wesep, R. A., Liaw, D., Clarke, K., Parsons, R., McKusick, V. A. and Geraghty, M. T. (1997) Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am. J. Med. Genet. 71, 489-493
20. Zhou, X. P., Hampel, H., Thiele, H., Gorlin, R. J., Hennekam, R. C. M., Parisi, M., Winter, R. M. and Eng, C. (2001) Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 358, 210-211
21. Kwon, C. H., Zhu, X. Y., Zhang, J. Y., Knoop, L. L., Tharp, R., Smeyne, R. J., Eberhart, C. G., Burger, P. C. and Baker, S. J. (2001) Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat. Genet. 29, 404-411
22. Grussenmeyer, T., Scheidtmann, K. H., Hutchinson, M. A., Eckhart, W. and Walter, G. (1985) Complexes of polyoma virus medium T antigen and cellular proteins. Proc. Natl. Acad. Sci. U.S.A. 82, 7952-7954
23. 22a Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
24. Kolb, A. J., Kaplita, P. V., Hayes, D. J., Park, Y. W., Pernell, C., Major, J. S. and Mathis, G. (1998) Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discov. Today 3, 333-342
25. Garcia-Echeverria, C., Traxler, P. and Evans, D. B. (2000) ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 20, 28-57
26. Madhusudan, Trafny, E. A., Xuong, N. H., Adams, J. A., Teneyck, L. F., Taylor, S. S. and Sowadski, J. M. (1994) cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer. Protein Sci. 3, 176-187
27. Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J. and Roth, R. A. (1999) Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 274, 21528-21532
28. Nesterov, A., Lu, X., Johnson, M., Miller, G. J., Ivashchenko, Y. and Kraft, A. S. (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 276, 10767-10774
29. Rokhlin, O. W., Guseva, N. V., Tagiyev, A. F., Glover, R. A. and Cohen, M. B. (2002) Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 52, 1-11
30. Dumas, J. (2001) Protein kinase inhibitors: emerging pharmacophores 1997-2000. Expert Opin. Ther. Pat. 11, 405-429
31. Bridges, A. J. (2001) Chemical inhibitors of protein kinases. Chem. Rev. 101, 2541-2571
32. Taylor, S. S. and Radzio-Andzelm, E. (1997) Protein kinase inhibition: natural and synthetic variations on a theme. Curr. Opin. Chem. Biol. 1, 219-226
33. Kobe, B., Heierhorst, J., Feil, S. C., Parker, M. W., Benian, G. M., Weiss, K. R. and Kemp, B. E. (1996) Giant protein kinases: domain interactions and structural basis of autoregulation. EMBO J. 15, 6810-6821
34. Taylor, S. S., Buechler, J. A., and Yonemoto, W. (1990). c-AMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu. Rev. Biochem. 59, 971-1005
35. Knighton, D. R., Pearson, R. B., Sowadski, J. M., Means, A. R., Ten Eyck, L. F., Taylor, S. S. and Kemp, B. E. (1992) Structural basis of the intrasteric regulation of myosin light chain kinases. Science 258, 130-135
36. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (London) 382, 325-331
37. Scapin, G. (2002) Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today 7, 601-611
38. Xu, W. Q., Harrison, S. C. and Eck, M. J. (1997) Three-dimensional structure of the tyrosine kinase c-Src. Nature (London) 385, 595-602
39. Sicheri, F., Moarefi, I. and Kuriyan, J. (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature (London) 385, 602-609
40. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. and Saltiel, A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494
41. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., Saltiel, A. R., Alessi, D. R., Cuenda, A. and Cohen, P. (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 92, 7686-7689
42. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S. and Regan, J. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9, 268-272
43. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F. et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632
44. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., Sawyers, C. L. and Fry, D. W. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Mechanism of action of erbB tyrosine kinase inhibitors. N. Engl. J. Med. 344, 1031-1037
45. Demetri, G. D. (2002) Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (ST1571). Eur. J. Cancer 38 (Suppl. 5), S52-S59
46. Arteaga, C. L. (2003) ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 284, 122-130
47. Arteaga, C. L. (2003) Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? Clin. Cancer Res. 9, 1231-1232
48. Laine, J., Kunstle, G., Obata, T. and Noguchi, M. (2002) Differential regulation of Akt kinase isoforms by the members of TCL1 oncogene family. J. Biol. Chem. 277, 3743-3751
49. Cho, H., Thorvaldsen, J. L., Chu, Q. W., Feng, F. and Birnbaum, M. J. (2001) Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349-38352
50. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q. W., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I. and Birnbaum, M. J. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728-1731
51. Page, C., Lin, H. J., Jin, Y., Castle, V. P., Nunez, G., Huang, M. and Lin, J. Y. (2000) Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20, 407-416
52. Bellacosa, A., DeFeo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M. H., Dubeau, L., Scambia, G., Masciullo, V. et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280-285
53. Staal, S. P. (1987) Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 84, 5034-5037